[Phase II study of the treatment of CML blast crisis with vindesine and prednisone].

Abstract

16 patients with CML-BC were treated with vindesine/prednisone. Complete remissions were achieved in 3 cases which lasted 1 month (myeloid), 3 months (mixed) and 5 months (lymphoid). Minor responses, including less than 50% reduction of absolute blast counts and marked regression of organomegaly with a median duration of 3 weeks, occurred in 11 patients. Two patients did not respond to VDS. Leukopenia and thrombocytopenia were severe and prolonged, independent of their phenotype.

• Authors: U Jehn, J Mezger
• Journal: Onkologie (Onkologie) Vol. 7 Issue 6 Pg. 342-5 (Dec 1984) ISSN: 0378-584X [Print] Switzerland
• Vernacular Title: Phase-II-Studie zur Behandlung der CML-Blastenkrise mit Vindesin und Prednison.
• PMID: 6396561 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• Vinblastine
• Vindesine
• Prednisone

Topics

• Adolescent
• Adult
• Aged
• Antineoplastic Agents (therapeutic use)
• Clinical Trials as Topic
• Drug Evaluation
• Female
• Humans
• Leukemia, Myeloid (drug therapy, pathology)
• Male
• Middle Aged
• Pancytopenia (chemically induced)
• Prednisone (administration & dosage, adverse effects)
• Vinblastine (administration & dosage, adverse effects, analogs & derivatives)
• Vindesine